Jul. 1 at 2:09 PM
$SXTP 60 Degrees Pharmaceuticals reported a positive recommendation from its Data Safety Monitoring Board for continuation of the B-FREE Phase 2 study of tafenoquine in chronic babesiosis patients with severe fatigue. The DSMB found no safety concerns in the initial cohort, supporting ongoing trial progression. The study evaluates an ARAKODA-based regimen, expanding investigation of a drug currently FDA-approved only for malaria prophylaxis.
